Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
Crossref DOI link: https://doi.org/10.1186/S12931-016-0361-4
Published Online: 2016-05-04
Published Print: 2016-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Celli, Bartolomé R.
Decramer, Marc
Liu, Dacheng
Metzdorf, Norbert
Asijee, Guus M.
Tashkin, Donald P.
Funding for this research was provided by:
Boehringer Ingelheim
